PSI Webinar(s): Causal inference in Clinical Trials
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
Date: Wednesday 7th September 2022
Time: 16:00-17:00 BST
Speakers: Yongming Qu (Eli Lilly) and Solomon Harrar (University of Kentucky)
Our next journal club features two papers on the topic of “Estimating Treatment Effects”. Please join us to hear Yongming Qu (Eli Lilly) and Solomon Harrar (University of Kentucky) present their recent work. The webinar will be chaired by Ilya Lipkovich (Eli Lilly)
To view the flyer for this event, please click here.
This event is sponsored by Wiley.
This event is open to both Members and Non-Members of PSI.
REGISTER HERE: https://us06web.zoom.us/webinar/register/WN_YLURM98nQF6aSfAKxR91VA
Yongming Qu (Eli Lilly): Estimating the treatment effect for adherers using multiple imputation
Ye, Z, Harrar, SW. Estimation of multivariate treatment effects in contaminated clinical trials.
Pharmaceutical Statistics. 2022; 21( 3): 535- 565. doi:10.1002/pst.2185
Solomon Harrar (University of Kentucky): Estimation of multivariate treatment effects in contaminated clinical trials
Luo, J, Ruberg, SJ, Qu, Y. Estimating the treatment effect for adherers using multiple imputation.
Pharmaceutical Statistics. 2022; 21( 3): 525- 534. doi:10.1002/pst.2184
For each of these published papers there will be a 20 minute presentation by the author, followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
In a world buzzing with artificial intelligence, can you distinguish between what's AI-generated and what's not? The session promises to showcase machine-generated content, challenging your perceptions, and luring you into the fascinating world of AI technology.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This course consists of 5 x 2 hour training sessions run over 5 weeks. For those who cannot attend the date and time provided, there will be a recording provided and a follow-up 1 hour Q and A session. Participation will provide access to extensive course materials in the form of a “bookdown” site. However, this is designed as a hands-on, interactive course. Both you and the trainers will work entirely within the RStudio Cloud development environment, which will remain accessible between virtual sessions in order to further explore and cement your understanding.
The Pre-Clinical SIG Workshop returns for 2024, bringing you a two half-days event, starting with a course on pre-clinical design of experiments. We will also have speakers on topics such as statistics and genetic toxicology, the new and promising OMARS DOE and ANOVA-type.
Are you a member of PSI looking to further your career or help develop others - why not sign up to the PSI Mentoring scheme? You can expand your network, improve your leadership skills and learn from more senior colleagues in the industry.
Suitable for PhD candidates in statistics or a related discipline. Full-time for 10-12 weeks in Summer 2024. Remote working, from the United States or the United Kingdom
UCB invites TWO candidates interested in a career in drug development to undertake a medical statistician apprenticeship.
The Principal DMC Statistician works primarily in the production and quality control.
Head of Respiratory Vaccines Clinical Statistics role has portfolio leadership for statisticians aligned to vaccine development in the area of Respiratory disease, providing statistical leadership for Clinical Development and Commercialization.
BioMarin is the world leader in delivering therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases.